
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
1988 they contracted exclusively to Quincy Research Center, are considered the first CRO and was known as Berger Boyer & Associates until 2000, when they become B&B Clinical Innovations.
Subsequently purchased by






